Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚨 Don’t miss your updated list of AI-picked stocks for this month
Pick Stocks with AI
Why Is Blueprint Medicines (BPMC) Down 21.6% Since Last Earnings Report?
By Zacks Investment ResearchStock MarketsMar 13, 2020 11:30PM ET
www.investing.com/analysis/why-is-blueprint-medicines-bpmc-down-216-since-last-earnings-report-200516068
Why Is Blueprint Medicines (BPMC) Down 21.6% Since Last Earnings Report?
By Zacks Investment Research | Mar 13, 2020 11:30PM ET It has been about a month since the last earnings report for Blueprint Medicines (BPMC). Shares have lost about 21.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Blueprint Medicines due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Blueprint Medicines Q4 Loss Narrows, Revenues Top Mark
Blueprint Medicines incurred a loss of $1.35 per share in the fourth quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of $1.71 and also the year-ago quarter’s loss of $1.83.
Collaboration revenues comprising the company’s total revenues came in at $51.5 million, reflecting a significant rise year over year. The top line also comprehensively surpassed the Zacks Consensus Estimate of $24 million.
Revenues generated by Blueprint Medicines are all related to its partnership with Roche, CStone Pharmaceuticals and Clementia Pharmaceuticals for the development and commercialization of its pipeline candidates.
Quarter in Detail
Research and development expenses were $88.6 million, up 25.7% from the year-ago figure, mainly due to higher spending associated with the lead candidates’ development and increased personnel costs.
General and administrative expenses were $32.3 million, up 137.5% year over year on account of higher personnel fees, infrastructure costs and other commercial costs.
Blueprint Medicines had cash, cash equivalents and marketable securities of $548 million as of Dec 31, 2019, lower than the sequential quarter’s level of $594.5 million.
How Have Estimates Been Moving Since Then?
Estimates review followed a downward path over the past two months. The consensus estimate has shifted -5.94% due to these changes.
VGM Scores
Currently, Blueprint Medicines has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Blueprint Medicines has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report
Original post
Related Articles
Value Takes Lead, Bonds Regain Favor – Is 2025 the Year of the Great...
By Brian Gilmartin - Mar 03, 2025
With 2 full months of the year completed, the S&P 500 (SPY) is up +1.38% while the Barclay’s Aggregate is +2.76% YTD, leaving a 60% / 40% balanced portfolio up +1.93% YTD as...
1 Stock to Buy, 1 Stock to Sell This Week: Costco, Foot Locker
By Jesse Cohen - Mar 02, 2025
1
• Trump’s trade war, U.S. jobs report, and last batch of Q4 earnings will be in focus this week. • Costco's earnings report is seen as a potential catalyst for growth, making it a...
3 Key Charts Suggesting That the Markets Remain on a Ledge
By Craig Thompson - Mar 03, 2025
The market has taken a turn this past month, with volatility picking up and key technical indicators signaling caution. The S&P 500, which had been trading within a...
Why Is Blueprint Medicines (BPMC) Down 21.6% Since Last Earnings Report?
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.